Moberg Pharma AB (FRA:MB8) Buyback Yield %: 0.02 (As of Jul. 06, 2026)

What is Moberg Pharma AB Buyback Yield %?

Moberg Pharma AB FRA:MB8 +0.50% 60 Buyback Yield % is 0.02 as of Jul. 06, 2026. GuruFocus rates FRA:MB8 with a GF Score™ of 60/100 and a GF Value™ of €1.06. The stock has 1 warning sign investors should review. Among 291 Drug Manufacturers companies, Moberg Pharma AB ranks better than 68.38% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Moberg Pharma AB's current buyback yield was 0.02%.

Moberg Pharma AB Buyback Yield % Related Terms

Moberg Pharma AB Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Moberg Pharma AB's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Moberg Pharma AB Buyback Yield % Chart

Moberg Pharma AB Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec21

Dec22

Dec23

Dec24

Buyback Yield %

Get a 7-Day Free Trial

0.00

-55.17

-53.27

-22.11

-71.89

Moberg Pharma AB Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Buyback Yield %	Get a 7-Day Free Trial															-87.82	-2.28	0.00	0.01	0.01

FRA:MB8 vs ZTS, UTHR: Buyback Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Moberg Pharma AB Buyback Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Moberg Pharma AB's Buyback Yield % falls into.

Save Embed

60GF Score

Moberg Pharma AB FRA:MB8

Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Moberg Pharma AB Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Moberg Pharma AB's Buyback Yield for the fiscal year that ended in Dec. 2024 is calculated as

Buyback Yield	=	Net Issuance of Stock			/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	/	Market Cap
	=	- (0	+	28.18)	/	39.1987735
	=	-71.89%

Moberg Pharma AB's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield	=	Net Issuance of Stock		(TTM)		/	Market Cap
	=	- (Repurchase of Stock	+	Issuance of Stock)	(TTM)^**	/	Market Cap
	=	- (-0.006	+	0)		/	41.6663865
	=	0.01%

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →

What does a Buyback Yield % of 0.02 mean?

Moberg Pharma AB (FRA:MB8) has a Buyback Yield % of 0.02 as of Jul. 06, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Moberg Pharma AB and its competitors. According to the industry distribution chart, Moberg Pharma AB ranks #92 out of 291 companies in the Drug Manufacturers industry, placing it in the top 31.6%.

Is Moberg Pharma AB's Buyback Yield % too high?

Moberg Pharma AB's current Buyback Yield % is 0.02. Based on the distribution chart, Moberg Pharma AB ranks #92 out of 291 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Moberg Pharma AB has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.

How does Moberg Pharma AB's Buyback Yield % compare to ZTS and UTHR?

According to the Drug Manufacturers industry distribution chart, Moberg Pharma AB ranks #92 out of 291 companies for Buyback Yield %. This puts Moberg Pharma AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Buyback Yield % for a Drug Manufacturers company?

A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Buyback Yield % mean?

A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Moberg Pharma AB and its competitors. Moberg Pharma AB's current Buyback Yield % is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Moberg Pharma AB stock overvalued right now?

Moberg Pharma AB (FRA:MB8) has a current Buyback Yield % of 0.02. The stock's GF Value™ is €1.06, compared to a current price of €0.80 — trading 24.3% below its estimated fair value. The current Buyback Yield % is 0.02. Moberg Pharma AB's overall GF Score™ is 60/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Buyback Yield % calculated?

Buyback Yield % is calculated from a company's financial statements. For Moberg Pharma AB (FRA:MB8), the current Buyback Yield % is 0.02 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Moberg Pharma AB (FRA:MB8) Overvalued in 2026?

Based on GuruFocus' analysis, Moberg Pharma AB stock appears to be undervalued. The current stock price of €0.80 is trading 24.3% below its estimated GF Value™ of €1.06.

Key valuation signals for FRA:MB8:

Buyback Yield %: 0.02
GF Value™: €1.06 vs. price of €0.80 (24.3% below fair value)
GF Score™: 60/100 with 1 warning sign

No single metric tells the full story. See the FRA:MB8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Moberg Pharma AB Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies OSTO:CINPHA OSTO:ENZY OSTO:NANEXA OSTO:KLAR OSTO:EQL OSTO:DICOT XSAT:ACUC OSTO:VIVE OSTO:NEWBRY XSAT:ODI XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges MBGPF:USA MOB:Sweden

Address Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51

Website https://www.mobergpharma.se

Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.

60GF Score

Get the complete analysis for FRA:MB8

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.80

Price

€1.06

GF Value

View FRA:MB8 Analysis

See Buyback Yield % data for all stocks →